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the treatment of obesity: study protocol for
a randomized controlled trial
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Lincoln Rothwell6, Daniel Oertli1 and Urs Zingg2
Abstract
Background: Laparoscopic Roux-en-Y gastric bypass (LRYGB) is considered the gold standard in bariatric surgery,
achieving durable long-term weight loss with improvement of obesity-related comorbidities. Lately, the laparoscopic
mini gastric bypass (LMGB) has gained worldwide popularity with similar results to LRYGB in terms of weight loss and
comorbidity resolution. However, there is a lack of randomized controlled trials (RCT) comparing LMGB and LRYGB. This
article describes the design and protocol of a randomized controlled trial comparing the outcomes of these two
bariatric procedures.
Methods/Design: The trial is designed as a single center, randomized, patient and observer blinded trial. The relevant
ethics committee has approved the trial protocol. To demonstrate that LMGB is not inferior to LRYGB in terms of
excess weight loss (EWL) the study is conducted as a non-inferiority trial with the sample-size calculations performed
accordingly. EWL 12 months after surgery is the primary endpoint, whereas 3-year EWL, morbidity, mortality, remission
of obesity related comorbidities, quality of life (QOL) and hormonal and lipid profile changes are secondary endpoints.
Eighty patients, 18 years or older and with a body mass index (BMI) between 35 and 50 kg/m2 who meet the Swiss
guidelines for the surgical treatment of morbid obesity will be randomized. The endpoints and baseline measurements
will be assessed pre-surgery, peri-surgery and post-surgery (fixed follow up measurements are at discharge and at the
time points 6 weeks and 12 and 36 months postoperatively).
Discussion: With its 3-year follow up time, this RCT will provide important data on the impact of LMGB and LRYGB on
EWL, remission of comorbidities, QOL and hormonal and lipid profile changes.
Trial registration: ClinicalTrials.gov, NCT02601092. Registered on 28 September 2015.
Keywords: Randomized controlled trial, Roux-en-Y gastric bypass, Mini gastric bypass, Outcome, Excess weight loss
Background
The globally growing incidence of obesity and its related
comorbidities is one of the most challenging public
health issues [1]. Morbid obesity reduces life expectancy,
in particular among younger adults [2]. Bariatric surgery,
the only effective treatment for morbidly obese patients,
has shown effective long-term weight loss and significant
reduction of obesity-related comorbidities and mortality
in randomized controlled trials (RCT) [3–5]. The laparo-
scopic Roux-en-Y gastric bypass (LRYGB) is considered
the gold standard among the different bariatric proce-
dures, achieves durable long-term weight loss and im-
proves obesity-related comorbidities [6, 7]. The
laparoscopic mini gastric bypass (LMGB), first reported
by Rutledge et al. [8], has recently gained popularity as a
new procedure for the treatment of morbid obesity.
LMGB is suggested to be a technically less demanding
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operation compared to LRYGB and offers comparable
benefits. Several studies have been published assessing
the efficacy and safety of LMGB. The first and only ran-
domized controlled trial comparing the LRYGB to
LMGB was carried out by Lee et al. in 2005 [9]. The au-
thors observed excess weight loss (EWL) of 64.9% after
LMGB and of 64.4% after one and two years, respect-
ively. In comparison, patients with LRYGB had EWL of
58.7% and 60.0%, respectively. Excess weight (EW) is de-
fined as the amount of weight that is in excess of the
ideal body weight (IBW), which is determined as a body
mass index (BMI) of 25 kg/m2. Therefore, EWL is the
quotient of weight loss and EW. In addition, LMGB pa-
tients had fewer postoperative complications and shorter
hospitalization.
Given the increasing number of bariatric procedures
performed worldwide [10], the impact on weight loss,
morbidity and mortality of LMGB in comparison to
LRYGB needs to be further assessed in randomized con-
trolled trials. Therefore, the aim of the current trial is to
analyze the EWL and resolution of comorbidities with
LMGB and LRYGB. Furthermore, the differences in hor-
mone levels and changes in the lipid status of patients
undergoing one of these two operations will be analyzed.
These results have the potential to influence bariatric
surgery guidelines profoundly and may bring additional
insights in the pathophysiology of the intestinal tract
after bariatric surgery.
Methods/Design
Primary objective
The general objective of this study is to compare LMGB
to LRYGB in terms of clinical outcome and safety
parameters. The primary objective of the study is to
evaluate the non-inferiority of LMGB in comparison to
LRYGB in terms of EWL (percent) one year after
surgery.
Secondary objective
The secondary objectives are the long-term effects of
LMGB on weight loss, the perioperative and postopera-
tive morbidity and the changes in different pathophysio-
logical parameters during the study period: EWL at
36 months, morbidity, mortality, operative time, length
of stay, subjective perception of appetite and satiety,
quality of life (QOL), incidence of dumping syndrome,
hormone levels (ghrelin, glucagon-like peptide 1, peptide
YY, insulin), bile acids and lipid profile and functionality.
Study design and site
This single center, randomized, controlled, patient and
observer blinded, non-inferiority trial is being conducted
at the Limmattal Hospital in Zurich-Schlieren, a refer-
ence center for bariatric surgery according to the Swiss
Study Group for Morbid Obesity (SMOB). The trial has
been registered on ClinicalTrials.gov under the identifier
NCT02601092. This protocol has been written in
accordance with the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) guidelines
(Additional file 1). A figure showing the planned visit
and examination schedule is presented in Fig. 1.
Sample size
A total of 80 patients will be randomized, with 40
patients assigned to each treatment arm. A loss of follow
up at one year of 2.5% is considered realistic and it has
been calculated to account for a dropout rate of 10%.
Inclusion criteria
Patients aged 18 years or older with a BMI between 35
and 50 kg/m2 and eligible for bariatric surgery according
to the SMOB guidelines will be enrolled.
Exclusion criteria
Patients will be excluded on the following basis:
 Missing informed consent
 Lack of conservative weight loss treatment over
2 years
 Malignancy
 Inflammatory bowel disease
 Expected lack of compliance after multidisciplinary
evaluation for surgery
 Pregnancy
 BMI over 50 kg/m2
Preoperatively, patients will be assessed by a nutrition-
ist, endocrinologist, psychiatrist and general surgeon. If
more than three appointments are not attended or if
there are any contraindications due to severe psychiatric
comorbidities, the operation will be postponed or
cancelled.
Randomization
Eligible patients, who give confirmed consent, are ran-
domly assigned to one of the two operating techniques.
Randomization will be performed using sequentially
numbered, sealed, opaque envelopes. Computer-
generated block randomization is used to ensure an
equal number of patients in each treatment group. The
block size used is not available from the study protocol
and is unknown to the investigator, to keep the potential
for selection bias at the lowest level possible. Patients
will be allocated to a study group by the operating sur-
geon immediately prior to the operation.
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Interventions
Patients will receive standard preoperative assessment
including endocrine, pulmonary function and cardiovas-
cular assessment, psychological assessment, gastroscopy
with Helicobacter pylori testing and abdominal ultra-
sound to check for liver size and gallstones. The oper-
ation will always be performed by the same surgeon with
experience of performing over 1000 bariatric procedures.
Blinded preoperative and postoperative follow up will be
independently performed by two study physicians. The
study design flow diagram is presented in Fig. 2.
Laparoscopic Roux-en-Y gastric bypass (LRYGB)
After gastroesophageal junction identification, the stom-
ach is transected with a linear stapler entering the lesser
sac 3–5 cm below the junction, creating a small gastric
pouch with a volume of approximately 30 ml. A 60-cm
biliopancreatic limb is measured and an antecolic end-
to-side gastroenterostomy is formed using a 25-mm cir-
cular stapler. A stapled side-to-side jejunojejunostomy is
formed 150 cm distally (Fig. 3). Intermesenteric and
Petersen spaces are closed with non-absorbable sutures.
All patients will be discharged on daily multivitamin and
calcium tablets. Vitamin levels will be assessed during
follow up and supplementation undertaken if required.
Laparoscopic mini gastric bypass (LMGB)
Stapled division of the stomach at the junction of the
body and antrum is undertaken, at a location where a je-
junal loop can be comfortably brought up (Fig. 4). A 36
French bougie is passed by the anesthetist and held
against the lesser curvature. A very long gastric pouch is
created by resection of the stomach parallel to the lesser
curvature towards the angle of His. No short gastric ves-
sels are divided. The bypassed stomach lies on the pa-
tients left, and the narrow lesser-curvature gastric pouch
lies on the patient’s midline to the right of the bypassed
stomach. A point is selected on the small bowel 200 cm
distal to the ligament of Treitz. The jejunal loop is
brought up lying antecolic, and a linear stapler (60 mm)
is used to join the stomach and the small bowel at this
point. The linear stapler enterotomy site is then closed
with a running suture. The greater omentum is tucked
between the gastric tube and the bypassed stomach [8].
Finally, Petersen’s space is closed with a non-absorbable
suture. All patients will be discharged with daily oral
Fig. 1 Schedule of enrollment, interventions, and assessments according to the Standard Protocol Items: Recommendations for Interventional Trials
(SPIRIT) guideline. LRYGB laparoscopic Roux-en-Y gastric bypass, LMGB laparoscopic mini gastric bypass, GERD gastroesophageal reflux disease, QOL
quality of life
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multivitamins and calcium tablets. Vitamin levels will be
assessed regularly during follow up and supplementation
undertaken if required.
Study visits
Physicians and study nurses blinded to the intervention
will perform study documentation and patient assess-
ment. Since the trial is designed as an observer and pa-
tient blinded RCT, information about the surgical
procedure will not be disclosed to any assessors during
the follow up examinations. There will be five study
visits in total. The first visit will be preoperative after
informed consent is obtained. Postoperatively, study
visits will be performed at discharge, 6 weeks and 12
and 36 months. Each study visit includes collection of
data on weight, blood tests, in particular, metabolic pa-
rameters such as hormonal assessment, glucose levels
and lipid profile. Measurement of metabolic parameters
will be conducted preoperatively and 6 weeks and 12
and 36 months postoperatively after a 12-hour fast and
at 60 and 120 minutes after a standardized test meal
(375 kcal). In addition, questionnaires will be also
assessed (Gastrointestinal Quality of Life Index
(GIQLI), Simplified Nutritional Appetite Questionnaire
(SNAQ), Gastroesophageal Reflux Disease Question-
naire (GERDQ), Bariatric Analysis And Reporting Out-
come System (BAROS) and the Sigstad score) at each
visit. Furthermore, triglycerides (TG), total cholesterol,
high-density lipoprotein (HDL), low-density lipoprotein
(LDL), ghrelin, glucagon-like peptide-1 (GLP-1), pep-
tide YY (PYY), glucose, insulin and bile acids will also
be evaluated. Postoperatively additional data on mor-
bidity (surgical and non-surgical short-term and long-
term complications) and mortality will be collected.
Study endpoints
Primary endpoint
The primary endpoint is the EWL at 12 months after
surgery (LRYGB or LMGB). For the EWL calculation
(percent) the pre-surgical total body weight (at the pa-
tient’s hospital entry time) and postsurgical total body
weight at one year postoperative is measured.
Secondary endpoints
 Long-term EWL at 36 months after surgery (in
percent)
 Early surgical and non-surgical complications
(≤30 days) according to the Clavien-Dindo classifica-
tion [11]
 Operation time
 Length of hospital stay
 Hormonal levels (ghrelin, GLP-1, PYY, glucose and
insulin)
 Lipid profile
 Bile acids
 Incidence of GERD
 Satiety degree
 Dumping
 Quality of life questionnaires
Fig. 2 Flow diagram of the study design. LMGB laparoscopic mini gastric bypass, LRYGB laparoscopic Roux-en-Y gastric bypass, BMI body mass index
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Levels of glucose, insulin and HbA1c will be deter-
mined for assessment of glucose homeostasis. TG, total
cholesterol, LDL cholesterol (LDL-C), HDL cholesterol
(HDL-C) and HDL/LDL cholesterol quotients will be
measured to create a lipid profile. Quality of life, satiety
degree, incidence of reflux and dumping will be in-
vestigated by questionnaires (GIQLI [12], SNAQ [13],
GERDQ [14], BAROS [15] and the Sigstad score
[16]). Secondary endpoints will be evaluated preopera-
tively, at discharge, 6 weeks and 12 and 36 months
postoperatively.
Blinding
With the exception of the team in the operating theatre,
all medical and non-medical practitioners and patients
will be blinded to the procedure. The procedure will be
named as study bypass in all medical records. Unblind-
ing is permitted in the case of surgical or medical com-
plications, emergency consultation or other ethical
considerations.
Statistical analyses
Sample size
If LMGB is non-inferior to LRYGB, 72 patients are re-
quired (36 patients per study arm) to have an 80%
chance that the lower limit of the one-sided 97.5% con-
fidence interval (equivalently a 95% two-sided confi-
dence interval), does not include the non-inferiority
limit of –10% EWL when assessed at 12 months. Given
an anticipated dropout rate of 10%, the total number of
patients to be included in the study is 80 (40 patients
per arm). The non-inferiority limit of –10% EWL was
chosen based on expert bariatric opinion. Furthermore
a standard deviation of 15 was assumed in both arms
according to a study from Lee et al. [9]. For further de-
tails on calculations see “Analysis of endpoints”.
Analysis of endpoints
The study results will be reported in adherence to the
extension of the Consolidated Standards of Reporting
Trials (CONSORT) statement from 2010 on reporting of
non-inferiority randomized trials [17]. Summary statis-
tics will be used to describe and compare patient charac-
teristics of all suitable but non-included patients and all
Fig. 3 Laparoscopic Roux-en-Y gastric bypass. The alimentary limb is
150 cm in length and is in the antecolic position. The mesentery defect
is closed with interrupted sutures
Fig. 4 Laparoscopic mini gastric bypass. The narrow gastric tube is
the diameter of a 36 French bougie. The gastroenterostomy is
created at the small bowel 200 cm distal to the Trietz ligament
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included patients (overall and stratified for the two treat-
ment arms). Study endpoints will primarily be analyzed
for the per protocol (PP) population. Sensitivity analysis
will be conducted for the intention-to-treat (ITT) popu-
lation. Thereby the ITT population includes all random-
ized patients in the groups to which they were randomly
assigned, regardless of their adherence to the entry cri-
teria, regardless of the treatment they actually received
and regardless of subsequent withdrawal or deviation
from the protocol. In the PP population all protocol vio-
lators, including anyone who switched groups or missed
measurements are excluded. For each group, number of
participants (denominator) included in each analysis and
whether the analysis was by original assigned groups will
be given. Additional sensitivity analysis will be used if,
despite all efforts taken to ensure complete data collec-
tion, the number of missing data is non-negligible or
could potentially bias the results and conclusions.
Analysis of primary endpoint
The primary endpoint is the EWL at 12 months post-
surgery. To examine non-inferiority of the experimental
compared to standard treatment, we assess if the two-
sided confidence interval of the difference between the
mean EWL in the experimental treatment group and the
mean EWL in the standard treatment group does not
include the non-inferiority limit of –10% EWL.
Analysis of secondary endpoints
To investigate non-inferiority of the experimental treat-
ment in the long term, analysis used for the primary
endpoint will be repeated for EWL at 36 months post-
surgery. All other endpoints will be analyzed under the
assumption of superiority of the experimental treatment
compared to the standard treatment. To compare the
duration of surgery and the length of hospital stay
between the two treatment groups, the Wilcoxon
signed-rank test will be conducted (as we assume the
data to be right-skewed).
The number of perioperative and postoperative com-
plications will be analyzed by the chi-squared test or
Fisher’s exact test, dependent on the observed numbers
in a 2 × 2 contingency table. Additionally, we will com-
pare the risk for complications in the two groups by cal-
culating the risk difference with 95% confidence interval.
The other secondary endpoints will be investigated using
appropriate explorative methods and graphical
visualization.
Ethical considerations
Participation in this trial is strictly voluntary and
patients are allowed to exit the trial at any point without
explanation. All eligible patients are provided an infor-
mation sheet describing the study with sufficient
information for them to make an informed decision
about their participation in this study.
The study protocol, patients’ information sheets and
informed consent forms were approved by the local eth-
ics committee (Kantonale Ethikkommission Zürich,
KEK-ZH 2013-0389). In addition, insurance coverage for
general liability has been obtained. Patients who decline
to participate in this study are treated according to clin-
ical standards. These patients will not be included and
no study-specific follow up will be performed.
Participants’ confidentiality
The participants’ confidentiality is maintained at all
times. For confidentiality reasons, case report forms
(CRF) do not contain any personal data on study partici-
pants. Members of the ethics committees are obliged to
respect confidentiality and to refrain from divulging the
participants’ identities or any other personal information
they might be aware of. Source data in the hospital’s
electronic patient information systems are secured by
personal passwords and handled with respect to medical
secrecy.
Archiving and data retention
The investigator will maintain all study-related records,
such as CRFs, medical records, laboratory reports, in-
formed consent documents, safety reports, information
regarding participants who discontinued the trial and
other pertinent data. All records will be retained by the
investigator as long as required by the applicable laws
and regulatory requirements (10 years). Thereafter, all
data will be destroyed. The study is conducted in com-
pliance with this protocol and according to Good Clin-
ical Practice standards and legal regulations. Serum and
plasma samples will be stored in –80 °C freezers located
in the laboratories where the measurements will be per-
formed, which are the Center for Molecular Cardiology,
Institute of Veterinary Physiology at the University of
Zurich and the Laboratory of Translational Nutrition
Biology at the Federal Institute of Technology (ETH)
Zurich.
Freezers are provided with systems for 24-hour moni-
toring 7 days a week and reporting of temperature con-
trol with immediate remote alarm notification and
continuous data collection. This provides reliable and
durable environmental conditions for temperature re-
quirements of our samples. The serum and plasma sam-
ples will be stored for up to 5 years after the completion
or termination of the study. After this period, samples
will be disposed of as biohazardous waste following pol-
icies in force at the University of Zurich and at ETH
Zurich for the handling and disposal of biohazardous
material. At the completion of the study, there will be a
final reconciliation of samples collected, samples used
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and samples remaining. This reconciliation will be re-
ported on a samples accountability form, signed and
dated. All stored samples will be coded with a unique
storage identifier. The list of patient identifiers is access-
ible to UZ, TD, MK and EO. The scientists who will
carry out analyses on these materials are all experienced
researchers. They will not have access to personal identi-
fiers and will not be able to link the results of these tests
to personal identifier information. Access to the study
results will be restricted. A password system will be uti-
lized to control access. These passwords will be changed
on a regular basis. All reports prepared within this study
will be prepared such that no individual subject can be
identified.
Discussion
The positive effects of bariatric surgery on weight loss
and obesity-related comorbidities and mortality have
been widely demonstrated in long-term cohort trials and
short-term RCTs [6, 7, 18]. Over time, these procedures
have improved in respect to safety and can be offered at
a low mortality and morbidity rate [9, 19]. Various surgi-
cal options are available, with LRYGB and laparoscopic
sleeve gastrectomy (LSG) being the two most common
procedures. In addition, there are many new operations,
one of them being the LMGB. The quest for the most
effective bariatric procedure is not yet completed as
weight loss and improvement of metabolic status, co-
morbidity and quality of life have only been evaluated in
a few randomized controlled trials over a short-term
period. This study investigates the effectiveness of
LMGB compared to LRYGB, analyzing defined clinical
endpoints such as EWL, morbidity and mortality, meta-
bolic changes and quality of life. In addition, the RCT
will also answer some important questions about LMGB,
such as the course of obesity-related comorbidities and
dumping syndrome.
Furthermore, this study addresses the postoperative
course of hormones and lipids in these two different bar-
iatric procedures. It has been shown that after bariatric
operations the levels of hormones such as GLP-1 and
PYY are markedly increased [20]. Surgery improves
obesity-associated pro-atherogenic dyslipidemia as well,
which is characterized by high LDL and TG and low
HDL-C plasma levels. Low HDL-C levels are associated
with increased cardiovascular disease risk [21]. It was re-
cently demonstrated that RYGB improved the endothe-
lial protective properties of HDL in obese patients;
12 weeks after RYGB these properties were comparable
to those of healthy subjects although the patients were
still obese [22, 23]. Overall, the data indicate that RYGB
may achieve a dual HDL benefit, first the rapid restor-
ation of quality to more “healthy” HDL, and second the
increase in circulating HDL levels in the longer-term
period. The influence of LMGB on changes in lipopro-
tein profile and function and bile acids are not yet
known.
One issue surrounding LMGB that remains highly
controversial is the reflux of bile into the gastric pouch
and potentially into the esophagus. LMGB is often com-
pared to the refluxogenic loop gastric bypass (LGB) de-
scribed by Mason et al. [24], which consists of a large
gastric pouch transected horizontally with the gastrojeju-
nostomy close to the gastroesophageal junction. How-
ever, LMGB consists of a long narrow vertical gastric
pouch, thus, reflux into the esophagus is not believed to
be an LMGB-specific problem. By contrast, the surgical
technique of LMBG is comparable to the Billroth II pro-
cedure performed in peptic ulcer disease and gastric
cancer. In LMBG and Billroth II, the most important
parallel is the single anastomosis bypass of the duode-
num without a Roux-limb. The LMGB distance of the
gastrojejunostomy to the esophagus is longer than in
Billroth II. Furthermore, the biliopancreatic limb in
LMGB measures 200 cm compared to 60–80 cm for the
Billroth II operation.
In conclusion, the perfect bariatric procedure is tech-
nically easy and safe, and leads to adequate EWL and
improvement in obesity-related comorbidities. In con-
trast to the widely used LRYGB and LSG, the LMGB
might fulfill all of these criteria. The current study will
answer questions about safety, effectiveness and patho-
physiological changes in obesity-relevant hormones and
lipids after LMGB. These findings might therefore influ-
ence decision-making in bariatric surgery implementing
current surgical protocols towards personalized
indications.
Trial status
The trial has received ethics approval, and enrollment in
the trial has begun but has not yet reached full
enrollment.
Additional file
Additional file 1: SPIRIT checklist of included items in our clinical trial
protocol (DOCX 64 kb)
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